Table 2.
Baseline characteristics
| EBBINGHAUS | FOURIER16 | |
|---|---|---|
| Number of patients enrolled | 1974 | 27 564 |
| Mean age, y (SD) | 62.8 (8.7) | 62.5 (9.0) |
| Female sex | 543 (27.5) | 6769 (24.6) |
| Race | ||
| White | 1818 (92.1) | 23,458 (85.1) |
| Black or African American | 60 (3.0) | 669 (2.4) |
| Asian or other | 96 (4.9) | 3437 (12.5) |
| Region | ||
| North America | 479 (24.3) | 4571 (16.6) |
| Europe | 1359 (68.8) | 17 335 (62.9) |
| Latin America | 01 | 1823 (6.6) |
| Asia Pacific or South Africa | 136 (6.9) | 3835 (13.9) |
| Cardiac risk factors | ||
| HTN | 1657 (83.9) | 22,084 (80.1) |
| DM | 691 (35.0) | 10,081 (36.6) |
| Current cigarette use | 661 (33.5) | 7777 (28.2) |
| History of vascular disease | ||
| MI | 1481 (75.0) | 22,351 (81.1) |
| Nonhemorrhagic stroke | 388 (19.7) | 5337 (19.4) |
| PAD | 370 (18.7) | 3642 (13.2) |
| Statin use | ||
| High intensity | 1408 (71.3) | 19,103 (69.3) |
| Moderate intensity | 564 (28.6) | 8392 (30.4) |
| Low intensity or unknown | 2 (0.1) | 69 (0.3) |
| Ezetimibe | 101 (5.1) | 1440 (5.2) |
| Median lipid values at baseline, mg/dL (Q1–Q3) | ||
| LDL‐C2 | 92 (80‐108) | 92 (80‐109) |
| Total cholesterol | 168 (151‐189) | 168 (151‐189) |
| HDL‐C | 45 (38‐54) | 44 (37‐53) |
| TG | 131 (99‐179) | 133 (100‐182) |
Abbreviations: DM, diabetes mellitus; EBBINGHAUS, Evaluating PCSK9 Binding Antibody Influence on Cognitive Health in High Cardiovascular Risk Subjects; FOURIER, Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk; HDL‐C, high‐density lipoprotein cholesterol; HTN, hypertension; LDL‐C, low‐density lipoprotein cholesterol; MI, myocardial infarction; PAD, peripheral arterial disease; Q, quartile; SD, standard deviation; TG, triglycerides.
Data are presented as n (%) unless otherwise indicated.
Countries in Latin America did not participate in EBBINGHAUS.
LDL‐C was calculated based on the Friedewald equation, unless the calculated value was <40 mg/dL or the measured TG were >400 mg/dL, in which case preparative ultracentrifugation was performed with LDL‐C measured by β quantification.